BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 36240209)

  • 1. Preclinical efficacy of the Wnt/β-catenin pathway inhibitor BC2059 for the treatment of desmoid tumors.
    Braggio DA; Costas C de Faria F; Koller D; Jin F; Zewdu A; Lopez G; Batte K; Casadei L; Welliver M; Horrigan SK; Han R; Larson JL; Strohecker AM; Pollock RE
    PLoS One; 2022; 17(10):e0276047. PubMed ID: 36240209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of cultured desmoid cells with different CTNNB1 mutation status.
    Hamada S; Urakawa H; Kozawa E; Arai E; Ikuta K; Sakai T; Ishiguro N; Nishida Y
    Cancer Med; 2016 Feb; 5(2):352-60. PubMed ID: 26686699
    [TBL] [Abstract][Full Text] [Related]  

  • 3. β-Catenin Inhibitor BC2059 Is Efficacious as Monotherapy or in Combination with Proteasome Inhibitor Bortezomib in Multiple Myeloma.
    Savvidou I; Khong T; Cuddihy A; McLean C; Horrigan S; Spencer A
    Mol Cancer Ther; 2017 Sep; 16(9):1765-1778. PubMed ID: 28500235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Wnt targets genes are not differentially expressed in desmoid tumors bearing different activating β-catenin mutations.
    Timbergen MJM; Janssen ML; Verhoef C; Grünhagen DJ; Chibon F; Smid M; Sleijfer S; Wiemer EAC
    Eur J Surg Oncol; 2019 Apr; 45(4):691-698. PubMed ID: 30528042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between beta-catenin widespread nuclear expression and matrix metalloproteinase-7 overexpression in sporadic desmoid tumors.
    Matono H; Oda Y; Nakamori M; Tamiya S; Yamamoto H; Yokoyama R; Saito T; Iwamoto Y; Tsuneyoshi M
    Hum Pathol; 2008 Dec; 39(12):1802-8. PubMed ID: 18715618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human microRNA expression in sporadic and FAP-associated desmoid tumors and correlation with beta-catenin mutations.
    Cavallini A; Rotelli MT; Lippolis C; Piscitelli D; Digennaro R; Covelli C; Carella N; Accetturo M; Altomare DF
    Oncotarget; 2017 Jun; 8(26):41866-41875. PubMed ID: 28418912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TGF-β signaling promotes desmoid tumor formation via CSRP2 upregulation.
    Li Y; Fujishita T; Mishiro-Sato E; Kojima Y; Niu Y; Taketo MM; Urano Y; Sakai T; Enomoto A; Nishida Y; Aoki M
    Cancer Sci; 2024 Feb; 115(2):401-411. PubMed ID: 38041233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. β-catenin S45F mutation results in apoptotic resistance.
    Braggio D; Zewdu A; Londhe P; Yu P; Lopez G; Batte K; Koller D; Costas Casal de Faria F; Casadei L; Strohecker AM; Lev D; Pollock RE
    Oncogene; 2020 Aug; 39(34):5589-5600. PubMed ID: 32651460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of beta-catenin mutations in paraffin-embedded sporadic desmoid-type fibromatosis by mutation-specific restriction enzyme digestion (MSRED): an ancillary diagnostic tool.
    Amary MF; Pauwels P; Meulemans E; Roemen GM; Islam L; Idowu B; Bousdras K; Diss TC; O'Donnell P; Flanagan AM
    Am J Surg Pathol; 2007 Sep; 31(9):1299-309. PubMed ID: 17721184
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TGF-β and CTGF are Mitogenic Output Mediators of Wnt/β-Catenin Signaling in Desmoid Fibromatosis.
    Varghese S; Braggio DA; Gillespie J; Toland AE; Pollock R; Mayerson J; Scharschmidt T; Iwenofu OH
    Appl Immunohistochem Mol Morphol; 2017 Sep; 25(8):559-565. PubMed ID: 26894649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Pathogenesis of Sporadic Desmoid Tumours and Its Implications for Novel Therapies: A Systematised Narrative Review.
    McLean TD; Duchi S; Di Bella C
    Target Oncol; 2022 May; 17(3):223-252. PubMed ID: 35446005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Possible association between higher beta-catenin mRNA expression and mutated beta-catenin in sporadic desmoid tumors: real-time semiquantitative assay by TaqMan polymerase chain reaction.
    Saito T; Oda Y; Kawaguchi K; Tanaka K; Matsuda S; Tamiya S; Iwamoto Y; Tsuneyoshi M
    Lab Invest; 2002 Jan; 82(1):97-103. PubMed ID: 11796830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autophagy inhibition overcomes sorafenib resistance in S45F-mutated desmoid tumors.
    Braggio D; Koller D; Jin F; Siva N; Zewdu A; Lopez G; Batte K; Casadei L; Welliver M; Strohecker AM; Lev D; Pollock RE
    Cancer; 2019 Aug; 125(15):2693-2703. PubMed ID: 30980399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CTNNB1 S45F mutation predicts poor efficacy of meloxicam treatment for desmoid tumors: a pilot study.
    Hamada S; Futamura N; Ikuta K; Urakawa H; Kozawa E; Ishiguro N; Nishida Y
    PLoS One; 2014; 9(5):e96391. PubMed ID: 24788118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. β-Catenin mutation status and outcomes in sporadic desmoid tumors.
    Mullen JT; DeLaney TF; Rosenberg AE; Le L; Iafrate AJ; Kobayashi W; Szymonifka J; Yeap BY; Chen YL; Harmon DC; Choy E; Yoon SS; Raskin KA; Hornicek FJ; Nielsen GP
    Oncologist; 2013; 18(9):1043-9. PubMed ID: 23960186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the Notch pathway: A potential therapeutic approach for desmoid tumors.
    Shang H; Braggio D; Lee YJ; Al Sannaa GA; Creighton CJ; Bolshakov S; Lazar AJ; Lev D; Pollock RE
    Cancer; 2015 Nov; 121(22):4088-96. PubMed ID: 26349011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tegavivint and the β-Catenin/ALDH Axis in Chemotherapy-Resistant and Metastatic Osteosarcoma.
    Nomura M; Rainusso N; Lee YC; Dawson B; Coarfa C; Han R; Larson JL; Shuck R; Kurenbekova L; Yustein JT
    J Natl Cancer Inst; 2019 Nov; 111(11):1216-1227. PubMed ID: 30793158
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors.
    Lazar AJ; Tuvin D; Hajibashi S; Habeeb S; Bolshakov S; Mayordomo-Aranda E; Warneke CL; Lopez-Terrada D; Pollock RE; Lev D
    Am J Pathol; 2008 Nov; 173(5):1518-27. PubMed ID: 18832571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiation-induced Sarcomas Occurring in Desmoid-type Fibromatosis Are Not Always Derived From the Primary Tumor.
    Verschoor AJ; Cleton-Jansen AM; Wijers-Koster P; Coffin CM; Lazar AJ; Nout RA; Rubin BP; Gelderblom H; Bovée JV
    Am J Surg Pathol; 2015 Dec; 39(12):1701-7. PubMed ID: 26414222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical and Molecular Analyses Focusing on Mesenchymal Cells in Papillary Thyroid Carcinoma with Desmoid-Type Fibromatosis.
    Takada N; Mussazhanova Z; Hirokawa M; Nakashima M; Miyauchi A
    Pathobiology; 2018; 85(5-6):300-303. PubMed ID: 30223266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.